Drugs / [18F]F-PDL1-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07848243 | Feb 2026 → Jul 2027 expected | breast cancer, cervical squamous cell carcinoma, cutaneous melanoma, digestive system cancer +1 | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]F-PDL1-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07848243 ↗ |
| Modality | Diagnostic / imaging agent | “\[18F\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1” NCT07848243 ↗ |
| Route | Intravenous | “participants received intravenous \[18F\]F-PDL1-3” NCT07848243 ↗ |